Roche / Genentech clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-10
What changed in the last 30 days
75 trials changed in the last 30 days: 1 stopped, 21 with notable changes, 53 with minor changes only.
- Notable: TARBELA-PD · Effects and Safety of RO7568282 in Early Parkinson's Disease Phase changed: Phase 1/2 → Phase 2
- Notable: SKYSCRAPER-01 · Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab · Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer Results posted: Nov 9, 2026
- Minor: KRASCENDO 3 · Divarasib Compared With Investigator's Choice of Immunotherapy or Observation · Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) Trial sites expanded: 46 → 104 locations
- Minor: Enith2 · Enicepatide (RO7795068) · Obesity or Overweight and Type 2 Diabetes Trial sites expanded: 210 → 222 locations
- Minor: Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab · Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Primary and study completion moved earlier from Mar 31, 2027 to Dec 28, 2026
- Minor: OCARINA 3 · New Subcutaneous Formulation of Ocrelizumab · Multiple Sclerosis Primary completion date changed from estimate of Feb 15, 2028 to Sep 1, 2026
- Notable: TARBELA-AD · Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease Recruitment opened
- Notable: UmbrellaMAX · Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study Enrollment increased: 100 → 200 participants
- Minor: IMvigor011 · Atezolizumab Versus Placebo as Adjuvant Therapy · High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy Trial completed
- Minor: HINALEA 1 · Risdiplam Administered as an Early Intervention · Spinal Muscular Atrophy After Gene Therapy Enrollment closed, study ongoing
- Minor: Pertuzumab · Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial Primary and study completion pushed from Dec 31, 2026 to Mar 28, 2027
- Minor: WILL-EMI NIS · Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment Primary and study completion pushed from Nov 1, 2026 to Jan 18, 2027
- Minor: Sightspire · 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD Trial sites expanded: 61 → 64 locations
- Minor: PrevenTRON · Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trial sites expanded: 34 → 72 locations
- Minor: Enicepatide in Generally Healthy Adult Chinese Participants Enrollment closed, study ongoing
- Minor: AMETRINE-PEDS · Afimkibart (RO7790121) · Moderately to Severely Active Ulcerative Colitis Trial sites expanded: 26 → 29 locations
- Minor: Krascendo 2 · Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin · Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Trial sites expanded: 288 → 299 locations
- Minor: ZUPREME-3 · Petrelintide · Overweight or Obesity Trial sites expanded: 3 → 8 locations
- Minor: BREnnA · RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine · Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Trial sites expanded: 206 → 219 locations
- Minor: Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy · Previously Treated Multiple Myeloma Trial sites expanded: 1 → 5 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-05 | NCT07918846 A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity… | Phase 3 | Not Yet Recruiting |
| 2026-10-30 | NCT07905924 A Study to Evaluate the Safety and Effectiveness of Different Doses of RO7836748 Alone or… | Phase 1 | Not Yet Recruiting |
| 2026-10-22 | NCT07889648 A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in… | Phase 3 | Not Yet Recruiting |
| 2026-10-20 | NCT07883577 A Study of RO7821657 in Participants With Solid Tumors | Phase 1 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 55 | |
| Phase 1/2 | 23 | |
| Phase 2 | 51 | |
| Phase 2/3 | 3 | |
| Phase 3 | 90 | |
| Phase 4 | 9 |
Not charted: 19 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 49
Breast Cancer (30) · Multiple Sclerosis (24) · Lung Cancer (20) · Non-Small Cell Lung Cancer (NSCLC) (17) · Non-Hodgkin Lymphoma (15) · Obesity (12) · Dementia (11) · Multiple Myeloma (10) · Diabetes (9) · Alzheimer's Disease (8)
Get alerts when Roche / Genentech's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.